Studies on Nucleoproteins

Spitnik, Pnina; Lipshitz, Rakoma; Chargaff, Erwin

doi:10.1016/s0021-9258(18)66000-4

Cited by 64 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The near-unity ratio of lysine ¡phosphate in the protected or insoluble complex is consistent with the correlation between charge neutralization and insolubility (Spitnik et al, 1955), and with the protection of DNA against nuclease action by poly-4-vinylpyridine charged to various degrees by quaternization (Bach and Miller, 1966). Our data are also consistent with conductometric studies (Felsenfeld and Huang, 1959) which have shown that polylysine displaces an equivalent amount of divalent cation (Mn2+) from polynucleotides.…”

Section: Discussionsupporting

confidence: 62%

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*

Ha¹,

Sf²,

Yaron³

et al. 1966

Biochemistry

View full text Add to dashboard Cite

essentially the same chain length as the polylysine of the initial complex and is susceptible to cleavage by the original enzyme. Protection specificity, i.e., high Gp + Cp content of protected fragment, appears to be related to secondary structure and is eliminated by thermal denaturation. Implications of these data in terms of a model of protein-nucleic acid interaction are discussed.of this interaction on the hydrolysis of RNA by nucleases. In common with similar studies with deoxyribonucleic acid (DNA) (Spitnik et al., 1955) we have found that, at low salt concentrations (0.10 m) and neutral pH, the addition of polylysine to RNA in solution results in the formation of a precipitate as the two components approach charge equivalence. However, at low poly lysine: RNA ratios, complexes of these polyelectrolytes are soluble and amenable to study.

show abstract

Section: Discussionsupporting

confidence: 62%

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*

Ha¹,

Sf²,

Yaron³

et al. 1966

Biochemistry

View full text Add to dashboard Cite

show abstract

“…Investigators have been encouraged in pursuing the analogy with histones by the observations that basic residues are frequently clustered in the amino acid sequences of the histones (Smith et al, 1970). In addition, polylysine shares with histones the ability to completely inhibit in vitro transcription of DNA (Shih and Bonner, 1970a,b) and a preference for precipitating (A + T)-rich DNA (Spitnik et al, 1955;Leng and Felsenfeld, 1966;Brown and Watson, 1953;Crampton et al, 1954; Lucy and Butler, 1955;Johns and Butler, 1964).…”

mentioning

confidence: 99%

Optical properties of deoxyribonucleic acid-polylysine complexes

Carroll

1972

Biochemistry

100

View full text Add to dashboard Cite

“…Similar to LNPs, protein and nucleic acid NPs use a cationic protein (e.g., protamine) to ionically complex negatively charged nucleic acids. These NPs were first reported in 1955 41 and progressed to clinical trials in 2018 42 as a rabies vaccine. Second, the abundant blood protein albumin can be used as a NP wherein the hydrophobic pockets of the protein are used to adsorb hydrophobic cargo.…”

Section: Classes Of Therapeutic Vaccine and Imaging Technologiesmentioning

confidence: 99%

Micro and nanotechnologies: The little formulations that could

Stiepel

Duggan

Batty

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

The first publication of micro‐ and nanotechnology in medicine was in 1798 with the use of the Cowpox virus by Edward Jenner as an attenuated vaccine against Smallpox. Since then, there has been an explosion of micro‐ and nanotechnologies for medical applications. The breadth of these micro‐ and nanotechnologies is discussed in this piece, presenting the date of their first report and their latest progression (e.g., clinical trials, FDA approval). This includes successes such as the recent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines from Pfizer, Moderna, and Janssen (Johnson & Johnson) as well as the most popular nanoparticle therapy, liposomal Doxil. However, the enormity of the success of these platforms has not been without challenges. For example, we discuss why the production of Doxil was halted for several years, and the bankruptcy of BIND therapeutics, which relied on a nanoparticle drug carrier. Overall, the field of micro‐ and nanotechnology has advanced beyond these challenges and continues advancing new and novel platforms that have transformed therapies, vaccines, and imaging. In this review, a wide range of biomedical micro‐ and nanotechnology is discussed to serve as a primer to the field and provide an accessible summary of clinically relevant micro‐ and nanotechnology platforms.

show abstract

Studies on Nucleoproteins

Cited by 64 publications

References 17 publications

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*

Optical properties of deoxyribonucleic acid-polylysine complexes

Micro and nanotechnologies: The little formulations that could

Contact Info

Product

Resources

About

Studies on Nucleoproteins

Cited by 64 publications

References 17 publications

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes*

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes*

Optical properties of deoxyribonucleic acid-polylysine complexes

Micro and nanotechnologies: The little formulations that could

Contact Info

Product

Resources

About

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*

Protein-Nucleic Acid Interaction. I. Nuclease-Resistant Polylysine-Ribonucleic Acid Complexes^*